Breaking News Instant updates and real-time market news.

NSRGY

Nestle

$119.61 /

-3.58 (-2.91%)

05:02
05/19/22
05/19
05:02
05/19/22
05:02

Nestle downgraded to Market Perform from Outperform at Bernstein

Bernstein analyst Bruno Monteyne downgraded Nestle to Market Perform from Outperform with a price target of CHF 120, down from CHF 126. The shares have been a "great" haven for investors, but there aren't any catalysts that would prompt a "material step up" from current levels, Monteyne tells investors in a research note. The analyst says the current stock price reflects long-term organic growth of 5.6%, which is just above Bernstein's 5.5% growth estimate.

OTHER BREAKING NEWS FROM THE FLY

Downgrade
Repare Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley » 05:55
02/03/23
02/03
05:55
02/03/23
05:55
RPTX

Repare Therapeutics

$13.16 /

+0.62 (+4.94%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RPTX Repare Therapeutics
$13.16 /

+0.62 (+4.94%)

RPTX Repare Therapeutics
$13.16 /

+0.62 (+4.94%)

11/17/22 H.C. Wainwright
Repare Therapeutics price target lowered to $25 from $38 at H.C. Wainwright
06/06/22 H.C. Wainwright
Repare Therapeutics price target lowered to $38 from $54 at H.C. Wainwright
06/02/22 Piper Sandler
Piper ups Repare Therapeutics target after 'great deal' with Roche
04/12/22 Stifel
Stifel downgrades Repare Therapeutics after 'blow to synthetic lethality thesis'
RPTX Repare Therapeutics
$13.16 /

+0.62 (+4.94%)

General news
Energy Action: » 05:55
02/03/23
02/03
05:55
02/03/23
05:55
$ECON

Economic Data

/

+

Energy Action: Oil prices…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Upgrade
Neurocrine upgraded to Overweight from Equal Weight at Morgan Stanley » 05:54
02/03/23
02/03
05:54
02/03/23
05:54
NBIX

Neurocrine

$107.96 /

-2.045 (-1.86%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NBIX Neurocrine
$107.96 /

-2.045 (-1.86%)

NBIX Neurocrine
$107.96 /

-2.045 (-1.86%)

12/13/22 RBC Capital
Neurocrine CAH data appears pushed back, says RBC Capital
11/14/22 Evercore ISI
Neurocrine downgraded to In Line from Outperform at Evercore ISI
11/02/22 BMO Capital
Neurocrine price target raised to $101 from $78 at BMO Capital
11/02/22 Wells Fargo
Neurocrine price target raised to $120 from $110 at Wells Fargo
NBIX Neurocrine
$107.96 /

-2.045 (-1.86%)

NBIX Neurocrine
$107.96 /

-2.045 (-1.86%)

Downgrade
Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley » 05:53
02/03/23
02/03
05:53
02/03/23
05:53
IMRX

Immuneering

$4.16 /

+0.05 (+1.22%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IMRX Immuneering
$4.16 /

+0.05 (+1.22%)

IMRX Immuneering
$4.16 /

+0.05 (+1.22%)

12/20/22 Piper Sandler
Piper recommends 'down market cap' biotech exposure for 2023
09/30/22 Piper Sandler
Immuneering transitions to clinical stage with IND approval, says Piper Sandler
07/25/22 Piper Sandler
Immuneering CFO departure not a 'red flag,' says Piper Sandler
07/08/22 Chardan
Immuneering initiated with a Buy at Chardan
IMRX Immuneering
$4.16 /

+0.05 (+1.22%)

Earnings
Sanofi sees 2023 business EPS up at low single digit rate at CER » 05:53
02/03/23
02/03
05:53
02/03/23
05:53
SNY

Sanofi

$47.22 /

-1.505 (-3.09%)

Sanofi expects 2023…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SNY Sanofi
$47.22 /

-1.505 (-3.09%)

SNY Sanofi
$47.22 /

-1.505 (-3.09%)

01/31/23 Berenberg
Sanofi price target raised to EUR 100 from EUR 91 at Berenberg
12/21/22 Barclays
Sanofi, Pfizer settled first California Zantac bellwether case, says Barclays
12/16/22 Goldman Sachs
Sanofi reinstated with a Buy at Goldman Sachs
12/15/22 Guggenheim
Vaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential
SNY Sanofi
$47.22 /

-1.505 (-3.09%)

SNY Sanofi
$47.22 /

-1.505 (-3.09%)

SNY Sanofi
$47.22 /

-1.505 (-3.09%)

SNY Sanofi
$47.22 /

-1.505 (-3.09%)

Upgrade
Esperion upgraded to Equal Weight from Underweight at Morgan Stanley » 05:52
02/03/23
02/03
05:52
02/03/23
05:52
ESPR

Esperion

$5.91 /

-0.49 (-7.66%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ESPR Esperion
$5.91 /

-0.49 (-7.66%)

ESPR Esperion
$5.91 /

-0.49 (-7.66%)

12/07/22 H.C. Wainwright
H.C. Wainwright bullish on Esperion as CLEAR Outcomes meets primary endpoint
08/03/22 Credit Suisse
Esperion downgraded to Underperform from Neutral at Credit Suisse
05/04/22 JPMorgan
Esperion upgraded to Neutral on achievable estimates at JPMorgan
05/04/22 JPMorgan
Esperion upgraded to Neutral from Underweight at JPMorgan
ESPR Esperion
$5.91 /

-0.49 (-7.66%)

ESPR Esperion
$5.91 /

-0.49 (-7.66%)

ESPR Esperion
$5.91 /

-0.49 (-7.66%)

Earnings
Sanofi reports Q4 business EPS EUR 1.71, up 17.4% at CER » 05:52
02/03/23
02/03
05:52
02/03/23
05:52
SNY

Sanofi

$47.22 /

-1.505 (-3.09%)

IFRS EPS for Q4 was EUR…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SNY Sanofi
$47.22 /

-1.505 (-3.09%)

SNY Sanofi
$47.22 /

-1.505 (-3.09%)

01/31/23 Berenberg
Sanofi price target raised to EUR 100 from EUR 91 at Berenberg
12/21/22 Barclays
Sanofi, Pfizer settled first California Zantac bellwether case, says Barclays
12/16/22 Goldman Sachs
Sanofi reinstated with a Buy at Goldman Sachs
12/15/22 Guggenheim
Vaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential
SNY Sanofi
$47.22 /

-1.505 (-3.09%)

SNY Sanofi
$47.22 /

-1.505 (-3.09%)

SNY Sanofi
$47.22 /

-1.505 (-3.09%)

SNY Sanofi
$47.22 /

-1.505 (-3.09%)

Upgrade
Erasca upgraded to Overweight from Equal Weight at Morgan Stanley » 05:51
02/03/23
02/03
05:51
02/03/23
05:51
ERAS

Erasca

$4.16 /

+0.165 (+4.13%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ERAS Erasca
$4.16 /

+0.165 (+4.13%)

ERAS Erasca
$4.16 /

+0.165 (+4.13%)

  • 09
    Dec
ERAS Erasca
$4.16 /

+0.165 (+4.13%)

Downgrade
Cyteir downgraded to Underweight from Equal Weight at Morgan Stanley » 05:50
02/03/23
02/03
05:50
02/03/23
05:50
CYT

Cyteir Therapeutics

$1.61 /

+0.02 (+1.26%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CYT Cyteir Therapeutics
$1.61 /

+0.02 (+1.26%)

CYT Cyteir Therapeutics
$1.61 /

+0.02 (+1.26%)

01/30/23 BofA
Cyteir Therapeutics downgraded to Neutral at BofA after strategic prioritization
01/30/23 BofA
Cyteir Therapeutics downgraded to Neutral from Buy at BofA
01/20/23 JPMorgan
Cyteir Therapeutics downgraded to Neutral from Overweight at JPMorgan
09/09/22 Morgan Stanley
Cyteir downgraded at Morgan Stanley with time needed for data
CYT Cyteir Therapeutics
$1.61 /

+0.02 (+1.26%)

Downgrade
Meta Platforms downgraded to Reduce from Hold at HSBC » 05:48
02/03/23
02/03
05:48
02/03/23
05:48
META

Meta Platforms

$188.78 /

+35.675 (+23.30%)

HSBC analyst Nicolas…

HSBC analyst Nicolas Cote-Colisson downgraded Meta Platforms to Reduce from Hold with an unchanged price target of $110. The company's Q4 results showed higher engagement, but revenue was still down, the analyst tells investors in a research note. The firm says headwinds for the company include the macro environment, competition and regulation versus one "longer-term tailwind that is Meta's lead in Metaverse." The recent share rally leads HSBC to downgrade the shares to Reduce.

ShowHide Related Items >><<
META Meta Platforms
$188.78 /

+35.675 (+23.30%)

META Meta Platforms
$188.78 /

+35.675 (+23.30%)

05:13 Today DZ Bank
Meta Platforms upgraded to Hold from Sell at DZ Bank
02/02/23 Deutsche Bank
Meta Platforms price target raised to $200 from $125 at Deutsche Bank
02/02/23 RBC Capital
Meta Platforms price target raised to $225 from $160 at RBC Capital
02/02/23 Needham
Meta Platforms reported fundamentals still deteriorating, says Needham
META Meta Platforms
$188.78 /

+35.675 (+23.30%)

META Meta Platforms
$188.78 /

+35.675 (+23.30%)

META Meta Platforms
$188.78 /

+35.675 (+23.30%)

META Meta Platforms
$188.78 /

+35.675 (+23.30%)

Periodicals
Tesla's sales of China-made EVs up 10% y/y in January, Reuters reports » 05:44
02/03/23
02/03
05:44
02/03/23
05:44
TSLA

Tesla

$188.32 /

+7.05 (+3.89%)

Tesla sold 66,051…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TSLA Tesla
$188.32 /

+7.05 (+3.89%)

TSLA Tesla
$188.32 /

+7.05 (+3.89%)

01/30/23 Bernstein
Bernstein sees orders as 'most critical' to Tesla stock
01/30/23 Berenberg
Tesla upgraded to Buy from Hold at Berenberg
01/26/23 Morgan Stanley
Tesla FY23 earnings could bottom near $3 per share, says Morgan Stanley
01/26/23 Wedbush
Tesla price target raised to $200 from $175 at Wedbush
TSLA Tesla
$188.32 /

+7.05 (+3.89%)

TSLA Tesla
$188.32 /

+7.05 (+3.89%)

TSLA Tesla
$188.32 /

+7.05 (+3.89%)

TSLA Tesla
$188.32 /

+7.05 (+3.89%)

Downgrade
Stifel downgrades C.H. Robinson to Hold after 'sizable miss' » 05:43
02/03/23
02/03
05:43
02/03/23
05:43
CHRW

C.H. Robinson

$104.37 /

+2.36 (+2.31%)

Stifel analyst J. Bruce…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CHRW C.H. Robinson
$104.37 /

+2.36 (+2.31%)

CHRW C.H. Robinson
$104.37 /

+2.36 (+2.31%)

05:22 Today Stifel
C.H. Robinson downgraded to Hold from Buy at Stifel
02/02/23 BMO Capital
C.H. Robinson price target lowered to $85 from $90 at BMO Capital
02/02/23 Susquehanna
C.H. Robinson price target raised to $86 from $83 at Susquehanna
02/02/23 Wells Fargo
C.H. Robinson price target raised to $95 from $86 at Wells Fargo
CHRW C.H. Robinson
$104.37 /

+2.36 (+2.31%)

CHRW C.H. Robinson
$104.37 /

+2.36 (+2.31%)

CHRW C.H. Robinson
$104.37 /

+2.36 (+2.31%)

CHRW C.H. Robinson
$104.37 /

+2.36 (+2.31%)

Downgrade
RBC downgrades Spirit AeroSystems on supply chain issues » 05:40
02/03/23
02/03
05:40
02/03/23
05:40
SPR

Spirit AeroSystems

$36.06 /

-0.08 (-0.22%)

RBC Capital analyst Ken…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SPR Spirit AeroSystems
$36.06 /

-0.08 (-0.22%)

SPR Spirit AeroSystems
$36.06 /

-0.08 (-0.22%)

05:08 Today RBC Capital
Spirit AeroSystems downgraded to Sector Perform from Outperform at RBC Capital
01/09/23 Truist
Spirit AeroSystems price target raised to $42 from $39 at Truist
11/11/22 BofA
BofA double downgrades '737 story' Spirit AeroSystems to Underperform
11/11/22 BofA
Spirit AeroSystems downgraded to Underperform from Buy at BofA
SPR Spirit AeroSystems
$36.06 /

-0.08 (-0.22%)

SPR Spirit AeroSystems
$36.06 /

-0.08 (-0.22%)

SPR Spirit AeroSystems
$36.06 /

-0.08 (-0.22%)

Upgrade
Publicis upgraded to Overweight from Equal Weight at Barclays » 05:24
02/03/23
02/03
05:24
02/03/23
05:24
PUBGY

Publicis

$19.20 /

+0.822 (+4.47%)

Barclays analyst Julien…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PUBGY Publicis
$19.20 /

+0.822 (+4.47%)

PUBGY Publicis
$19.20 /

+0.822 (+4.47%)

01/31/23 Barclays
Publicis price target raised to EUR 68 from EUR 62.50 at Barclays
01/06/23 UBS
Publicis price target raised to EUR 71 from EUR 68 at UBS
12/16/22 Morgan Stanley
Publicis price target raised to EUR 53 from EUR 50 at Morgan Stanley
12/12/22 JPMorgan
Publicis price target raised to EUR 82 from EUR 75 at JPMorgan
Downgrade
C.H. Robinson downgraded to Hold from Buy at Stifel » 05:22
02/03/23
02/03
05:22
02/03/23
05:22
CHRW

C.H. Robinson

$104.37 /

+2.36 (+2.31%)

Stifel analyst J. Bruce…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CHRW C.H. Robinson
$104.37 /

+2.36 (+2.31%)

CHRW C.H. Robinson
$104.37 /

+2.36 (+2.31%)

02/02/23 BMO Capital
C.H. Robinson price target lowered to $85 from $90 at BMO Capital
02/02/23 Susquehanna
C.H. Robinson price target raised to $86 from $83 at Susquehanna
02/02/23 Wells Fargo
C.H. Robinson price target raised to $95 from $86 at Wells Fargo
02/02/23 Bernstein
C.H. Robinson price target lowered to $92 from $110 at Bernstein
CHRW C.H. Robinson
$104.37 /

+2.36 (+2.31%)

CHRW C.H. Robinson
$104.37 /

+2.36 (+2.31%)

CHRW C.H. Robinson
$104.37 /

+2.36 (+2.31%)

CHRW C.H. Robinson
$104.37 /

+2.36 (+2.31%)

Downgrade
Sallie Mae downgraded to Equal Weight from Overweight at Wells Fargo » 05:20
02/03/23
02/03
05:20
02/03/23
05:20
SLM

Sallie Mae

$14.82 /

-2.965 (-16.67%)

Wells Fargo analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SLM Sallie Mae
$14.82 /

-2.965 (-16.67%)

SLM Sallie Mae
$14.82 /

-2.965 (-16.67%)

01/10/23 JPMorgan
Sallie Mae price target raised to $18 from $17 at JPMorgan
01/06/23 Barclays
Sallie Mae price target raised to $22 from $20 at Barclays
11/11/22 Compass Point
Sallie Mae downgraded to Neutral at Compass Point following outperformance
11/10/22 Compass Point
Sallie Mae downgraded to Neutral from Buy at Compass Point
SLM Sallie Mae
$14.82 /

-2.965 (-16.67%)

SLM Sallie Mae
$14.82 /

-2.965 (-16.67%)

SLM Sallie Mae
$14.82 /

-2.965 (-16.67%)

Downgrade
Cognizant downgraded to Neutral from Outperform at Baird » 05:19
02/03/23
02/03
05:19
02/03/23
05:19
CTSH

Cognizant

$70.62 /

+1.78 (+2.59%)

Baird analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CTSH Cognizant
$70.62 /

+1.78 (+2.59%)

CTSH Cognizant
$70.62 /

+1.78 (+2.59%)

01/19/23 MoffettNathanson
Cognizant downgraded to Underperform from Market Perform at MoffettNathanson
01/15/23 UBS
Cognizant price target raised to $68 from $62 at UBS
01/13/23 BMO Capital
Cognizant price target raised to $71 from $65 at BMO Capital
01/09/23 BofA
Cognizant downgraded to Underperform from Neutral at BofA
CTSH Cognizant
$70.62 /

+1.78 (+2.59%)

CTSH Cognizant
$70.62 /

+1.78 (+2.59%)

CTSH Cognizant
$70.62 /

+1.78 (+2.59%)

Upgrade
Lundin Mining upgraded to Overweight from Equal Weight at Morgan Stanley » 05:19
02/03/23
02/03
05:19
02/03/23
05:19
LUNMF

Lundin Mining

$7.32 /

-0.28 (-3.68%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LUNMF Lundin Mining
$7.32 /

-0.28 (-3.68%)

LUNMF Lundin Mining
$7.32 /

-0.28 (-3.68%)

02/02/23 Credit Suisse
Lundin Mining price target raised to C$10.25 from C$8.25 at Credit Suisse
01/23/23 JPMorgan
Lundin Mining price target lowered to SEK 57 from SEK 65 at JPMorgan
01/18/23 Scotiabank
Lundin Mining price target raised to C$15 from C$12 at Scotiabank
01/17/23 Scotiabank
Lundin Mining price target lowered to C$9 from C$10 at Scotiabank
Downgrade
Aptiv downgraded to Peer Perform from Outperform at Wolfe Research » 05:16
02/03/23
02/03
05:16
02/03/23
05:16
APTV

Aptiv

$118.67 /

+3.97 (+3.46%)

Wolfe Research analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
APTV Aptiv
$118.67 /

+3.97 (+3.46%)

APTV Aptiv
$118.67 /

+3.97 (+3.46%)

01/23/23 Deutsche Bank
Aptiv named short-term buy idea at Deutsche Bank
01/19/23 Deutsche Bank
Deutsche Bank keeps Buy on Aptiv, lowers price target to $126
01/09/23 BofA
Aptiv downgraded to Neutral from Buy at BofA
12/15/22 RBC Capital
Aptiv price target lowered to $115 from $120 at RBC Capital
APTV Aptiv
$118.67 /

+3.97 (+3.46%)

APTV Aptiv
$118.67 /

+3.97 (+3.46%)

Upgrade
Meta Platforms upgraded to Hold from Sell at DZ Bank » 05:13
02/03/23
02/03
05:13
02/03/23
05:13
META

Meta Platforms

$188.78 /

+35.675 (+23.30%)

DZ Bank analyst Ingo…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
META Meta Platforms
$188.78 /

+35.675 (+23.30%)

META Meta Platforms
$188.78 /

+35.675 (+23.30%)

02/02/23 Deutsche Bank
Meta Platforms price target raised to $200 from $125 at Deutsche Bank
02/02/23 RBC Capital
Meta Platforms price target raised to $225 from $160 at RBC Capital
02/02/23 Needham
Meta Platforms reported fundamentals still deteriorating, says Needham
02/02/23 Jefferies
Meta Platforms price target raised to $225 from $175 at Jefferies
META Meta Platforms
$188.78 /

+35.675 (+23.30%)

META Meta Platforms
$188.78 /

+35.675 (+23.30%)

META Meta Platforms
$188.78 /

+35.675 (+23.30%)

META Meta Platforms
$188.78 /

+35.675 (+23.30%)

Downgrade
ING Groep downgraded to Hold from Buy at Societe Generale » 05:13
02/03/23
02/03
05:13
02/03/23
05:13
ING

ING Groep

$13.87 /

-0.77 (-5.26%)

Societe Generale analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ING ING Groep
$13.87 /

-0.77 (-5.26%)

ING ING Groep
$13.87 /

-0.77 (-5.26%)

01/27/23 Barclays
ING Groep price target raised to EUR 12.50 from EUR 11.50 at Barclays
12/06/22 JPMorgan
ING Groep price target raised to EUR 13.40 from EUR 13 at JPMorgan
11/18/22 Morgan Stanley
ING Groep price target raised to EUR 16 from EUR 14 at Morgan Stanley
11/18/22 Morgan Stanley
ING Groep price target raised, named a 'Top Pick' at Morgan Stanley
ING ING Groep
$13.87 /

-0.77 (-5.26%)

Downgrade
Kesko downgraded to Hold from Buy at Danske Bank » 05:12
02/03/23
02/03
05:12
02/03/23
05:12
KKOYY

Kesko

$11.47 /

-0.64 (-5.28%)

Danske Bank analyst Calle…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KKOYY Kesko
$11.47 /

-0.64 (-5.28%)

01/24/23 DNB Markets
Kesko initiated with a Buy at DNB Markets
Upgrade
EMS-Chemie upgraded to Buy from Hold at Kepler Cheuvreux » 05:11
02/03/23
02/03
05:11
02/03/23
05:11
EMSHF

EMS-Chemie

$670.30 /

+ (+0.00%)

Kepler Cheuvreux analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EMSHF EMS-Chemie
$670.30 /

+ (+0.00%)

12/13/22 Berenberg
EMS-Chemie price target raised to CHF 600 from CHF 590 at Berenberg
12/13/22 Stifel
EMS-Chemie downgraded to Hold from Buy at Stifel
10/31/22 Berenberg
EMS-Chemie downgraded to Hold from Buy at Berenberg
10/18/22 Baader Helvea
EMS-Chemie downgraded to Reduce from Add at Baader Helvea
Downgrade
Insurance Australia downgraded to Neutral from Overweight at JPMorgan » 05:11
02/03/23
02/03
05:11
02/03/23
05:11
IAUGY

Insurance Australia

$17.31 /

+0.13 (+0.76%)

JPMorgan analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IAUGY Insurance Australia
$17.31 /

+0.13 (+0.76%)

01/24/23 Goldman Sachs
Insurance Australia initiated with a Neutral at Goldman Sachs
01/11/23 JPMorgan
Insurance Australia upgraded to Overweight from Neutral at JPMorgan
Upgrade
Cardinal Health upgraded to Outperform from Neutral at Baird » 05:09
02/03/23
02/03
05:09
02/03/23
05:09
CAH

Cardinal Health

$76.33 /

+0.62 (+0.82%)

Baird analyst Eric…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CAH Cardinal Health
$76.33 /

+0.62 (+0.82%)

CAH Cardinal Health
$76.33 /

+0.62 (+0.82%)

01/31/23 UBS
Cardinal Health price target raised to $91 from $78 at UBS
11/22/22 Credit Suisse
Cardinal Health price target raised to $79 from $64 at Credit Suisse
11/14/22 Mizuho
Cardinal Health price target raised to $74 from $66 at Mizuho
11/07/22 Baird
Cardinal Health price target raised to $82 from $74 at Baird
CAH Cardinal Health
$76.33 /

+0.62 (+0.82%)

CAH Cardinal Health
$76.33 /

+0.62 (+0.82%)

CAH Cardinal Health
$76.33 /

+0.62 (+0.82%)

CAH Cardinal Health
$76.33 /

+0.62 (+0.82%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.